Tempus AI, Inc. reported significant financial results for the second quarter of 2026, with total net revenue reaching $382.5 million, a 22% increase from $314.6 million in the same period of 2025. The growth was driven by a 20% rise in Diagnostics revenue, which amounted to $289.3 million, and a 28% increase in Data and applications revenue, totaling $93.2 million. Despite the revenue growth, the company recorded a net income of $5.6 million for the quarter, a notable improvement compared to a net loss of $42.8 million in the prior year. For the first half of 2026, Tempus reported total revenue of $730.6 million, up 28% from $570.4 million in the first half of 2025, although it still faced a net loss of $120.3 million.
The company experienced a substantial increase in operating expenses, which rose to $458.4 million for the second quarter, compared to $376.4 million in the same quarter of 2025. This increase was primarily attributed to higher costs in selling, general, and administrative expenses, which grew by 25% to $225.8 million, largely due to increased stock-based compensation and personnel costs. Research and development expenses also rose significantly, reflecting Tempus's ongoing investment in product innovation and technology development.
Strategically, Tempus has been active in expanding its capabilities through acquisitions. The company completed the acquisition of Paige.AI, Inc. in August 2025, enhancing its digital pathology offerings, and it is in the process of acquiring Personalis, Inc. for $1.5 billion, which is expected to close in late 2026 or early 2027. These acquisitions are part of Tempus's strategy to broaden its dataset and strengthen its position in the healthcare technology market.
Operationally, Tempus reported an increase in the volume of tests performed, with approximately 238,000 tests conducted in the second quarter of 2026, up from 212,000 in the same quarter of 2025. The company has also expanded its customer base, serving over 9,000 physicians and collaborating with more than 250 biotech companies. As of June 30, 2026, Tempus had cash and cash equivalents of $599.6 million, providing a solid liquidity position to support its ongoing operations and strategic initiatives.
Looking ahead, Tempus anticipates continued revenue growth driven by increased demand for its diagnostic services and data applications. The company remains focused on expanding its product offerings and enhancing its technology platform to support personalized medicine. However, it acknowledges the challenges posed by market conditions and the need for ongoing investment in research and development to maintain its competitive edge.
About Tempus AI, Inc.
Tempus AI is a healthcare technology company specializing in precision medicine through Intelligent Diagnostics. It combines AI, genomic, clinical, and imaging data to develop personalized, accurate laboratory tests across oncology, neuropsychiatry, cardiology, and infectious diseases. Its platform integrates vast multimodal datasets, enabling data-driven therapy decisions, clinical trial matching, and drug discovery, serving healthcare providers, researchers, and life sciences companies worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov